# Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy

> **NCT01994239** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 120 (estimated)

## Conditions studied

- Adenocarcinoma of Prostate

## Interventions

- **DRUG:** Degarelix
- **RADIATION:** Pelvic Radiotherapy

## Key facts

- **NCT ID:** NCT01994239
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-12
- **Primary completion:** 2022-03
- **Final completion:** 2025-03
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01994239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01994239, "Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01994239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*